title: Elderly donors for HCV(+) versus non-HCV recipients: patient survival following liver transplantation.
abstract: BACKGROUND
  Chronic liver failure due to hepatitis C virus (HCV)-related cirrhosis is the leading indication for liver transplantation. Inferior long-term results have been reported for liver transplantation in HCV(+) patients, especially when marginal donor livers are utilized.
  
  
  OBJECTIVE
  The aim of this study was to analyze retrospectively the outcome of liver transplantation patients from elderly donors in the case of HCV(+) versus non-HCV recipients.
  
  
  METHODS
  Among 330 liver transplantations performed from January 1994 to December 2006, we selected 244 excluding acute hepatic failure, children, and retransplants. Among these patients we analyzed 232 subjects who underwent the piggyback technique. Donor risk index (DRI) as described by Feng et al was applied using 1.7 as a cutoff value. We used Kaplan-Meier survival and Cox hazard regression analyses. We studied 14 donor variables using descriptive statistical tests.
  
  
  RESULTS
  There were 148 (63.8%) HCV(+) recipients and 84 (36.2%) non-HCV liver transplant recipients. Among HCV(+) recipients, 130/148 (87.8%) patients received livers, from donors less than 50 years old, and 18/148 (12.2%), over 50 years. The descriptive statistics of patient categorical variables are shown in Table 1, and continuous variables in Table 2. The cumulative proportional survival curves are shown in Figs 1 and 2. Mortality predictive factors in HCV(+) liver transplant recipients with donor age > 50 years old as determined by Cox hazard regression showed that death risk was increased with hazard ratios for warm ischemia = 1.01 (P = .001); for red blood cell intraoperative requirements = 2.63 (P = .003); for Child-Turcotte-Pugh classification points = 2.25 (P = .04), and for DRI > 1.7 = 2.19 (P = .03). In conclusion, advancing donor age, as well as the use of nonideal donors, intraoperative bleeding, and prolonged warm ischemia, had an adverse influence on patient survival for HCV(+) recipients.
authors.affiliation: Unit of Liver Transplantation, Unicamp, São Paulo, Brazil. ilkaboin@yahoo.com
authors.forename: I F S F
authors.initials: IF
authors.lastname: Boin
authors.forename: E C
authors.initials: EC
authors.lastname: Ataide
authors.forename: M I
authors.initials: MI
authors.lastname: Leonardi
authors.forename: R
authors.initials: R
authors.lastname: Stucchi
authors.forename: T
authors.initials: T
authors.lastname: Sevá-Pereira
authors.forename: I W
authors.initials: IW
authors.lastname: Pereira
authors.forename: A R
authors.initials: AR
authors.lastname: Cardoso
authors.forename: C A
authors.initials: CA
authors.lastname: Caruy
authors.forename: A
authors.initials: A
authors.lastname: Luzo
authors.forename: L S
authors.initials: LS
authors.lastname: Leonardi
mesh_terms: D000328:Adult; D000367:Age Factors; D006526:Hepatitis C / Q000601:surgery*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016031:Liver Transplantation / Q000276:immunology / Q000401:mortality* / Q000502:physiology*; D018579:Patient Selection; D012189:Retrospective Studies; D018570:Risk Assessment; D016019:Survival Analysis; D017741:Survivors; D014019:Tissue Donors / Q000706:statistics & numerical data*
chemical_list: D007166:Immunosuppressive Agents